[1]
|
Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016[J]. Journal of the National Cancer Center, 2022. |
[2]
|
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020:GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71:209-249. |
[3]
|
中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版)[J].临床肿瘤学杂志, 2011, 16:929-946. |
[4]
|
中华人民共和国卫生和计划生育委员会.原发性肝癌诊疗规范(2017年版)[J].中国实用外科杂志, 2017, 37:705-720. |
[5]
|
中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗规范(2019年版)[J].中华消化外科杂志, 2020, 19:1-20. |
[6]
|
中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗指南(2022年版)[J].中华消化外科杂志, 2022, 21:143-168. |
[7]
|
中共中央国务院.《"健康中国2030"规划纲要》[EB/OL].(2016)[2022]. http://www.gov.cn/zhengce/2016
-10/25/content_5124174.htm. |
[8]
|
Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines:1. Introduction-GRADE evidence profiles and summary of findings tables[J]. J Clin Epidemiol, 2011, 64:383-394. |
[9]
|
Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines:3. Rating the quality of evidence[J]. J Clin Epidemiol, 2011, 64:401-406. |
[10]
|
Andrews JC, Schunemann HJ, Oxman AD, et al. GRADE guidelines:15. Going from evidence to recommendation-determinants of a recommendation's direction and strength[J]. J Clin Epidemiol, 2013, 66:726-735. |
[11]
|
Durieux N, Vandenput S, Pasleau F. OCEBM levels of evidence system[J]. Rev Med Liege, 2013, 68:644-649. |
[12]
|
Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2004, 130:417-422. |
[13]
|
Fan R, Papatheodoridis G, Sun J, et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis[J]. J Hepatol, 2020, 73:1368-1378. |
[14]
|
Johnson PJ, Pirrie SJ, Cox TF, et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers[J]. Cancer Epidemiol Biomarkers Prev, 2014, 23:144-153. |
[15]
|
Best J, Bechmann LP, Sowa JP, et al. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis[J]. Clin Gastroenterol Hepatol, 2020, 18:728-35 e4. |
[16]
|
Caviglia GP, Abate ML, Petrini E, et al. Highly sensitive alpha-fetoprotein, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxyprothrombin for hepatocellular carcinoma detection[J]. Hepatol Res, 2016, 46:E130-E135. |
[17]
|
Berhane S, Toyoda H, Tada T, et al. Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients[J]. Clin Gastroenterol Hepatol, 2016, 14:875-86 e6. |
[18]
|
Huang C, Fang M, Xiao X, et al. Validation of the GALAD model for early diagnosis and monitoring of hepatocellular carcinoma in Chinese multicenter study[J]. Liver Int, 2022, 42:210-223. |
[19]
|
Wang Y, Tian Y. miRNA for diagnosis and clinical implications of human hepatocellular carcinoma[J]. Hepatol Res, 2016, 46:89-99. |
[20]
|
Zhou J, Yu L, Gao X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma[J]. J Clin Oncol, 2011, 29:4781-8. |
[21]
|
Sheng X, Ji Y, Ren GP, et al. A standardized pathological proposal for evaluating microvascular invasion of hepatocellular carcinoma:a multicenter study by LCPGC[J]. Hepatol Int, 2020, 14:1034-47. |
[22]
|
Zhang X, Li J, Shen F, et al. Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2018, 33:347-54. |
[23]
|
Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death:the BRIDGE Study[J]. Liver Int, 2015, 35:2155-66. |
[24]
|
中国抗癌协会肝癌专业委员会转化治疗协作组.肝癌转化治疗中国专家共识(2021版)[J].中华消化外科杂志, 2021, 20:600-16. |
[25]
|
Kaseb AO, Hasanov E, Cao HST, et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma:a randomised, open-label, phase 2 trial[J]. The Lancet Gastroenterology&Hepatology, 2022, 7:208-18. |
[26]
|
Shi HY, Wang SN, Wang SC, et al. Preoperative transarterial chemoembolization and resection for hepatocellular carcinoma:a nationwide Taiwan database analysis of long-term outcome predictors[J]. J Surg Oncol, 2014, 109:487-93. |
[27]
|
Zhou WP, Lai EC, Li AJ, et al. A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma[J]. Ann Surg, 2009, 249:195-202. |
[28]
|
Singal AG, Lim JK, Kanwal F. AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma:Expert Review[J]. Gastroenterology, 2019, 156:2149-57. |
[29]
|
Sapena V, Enea M, Torres F, et al. Hepatocellular carcinoma recurrence after direct-acting antiviral therapy:an individual patient data meta-analysis[J]. Gut, 2022, 71:593-604. |
[30]
|
Kulik L, Heimbach JK, Zaiem F, et al. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation:A systematic review and meta-analysis[J]. Hepatology, 2018, 67:381-400. |
[31]
|
Lee S, Kim KW, Song GW, et al. The Real Impact of Bridging or Downstaging on Survival Outcomes after Liver Transplantation for Hepatocellular Carcinoma[J]. Liver Cancer, 2020, 9:721-33. |
[32]
|
Mazzaferro V, Citterio D, Bhoori S, et al. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL):a randomised, controlled, phase 2b/3 trial[J]. The Lancet Oncology, 2020, 21:947-56. |
[33]
|
Mehta N, Guy J, Frenette CT, et al. Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria:A Multicenter Study[J]. Clin Gastroenterol Hepatol, 2018, 16:955-64. |
[34]
|
Qu S, Worlikar T, Felsted AE, et al. Non-thermal histotripsy tumor ablation promotes abscopal immune responses that enhance cancer immunotherapy[J]. J Immunother Cancer, 2020, 8. |
[35]
|
Greten TF, Mauda-Havakuk M, Heinrich B, et al. Combined locoregional-immunotherapy for liver cancer[J]. J Hepatol, 2019, 70:999-1007. |
[36]
|
Mizukoshi E, Yamashita T, Arai K, et al. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma[J]. Hepatology, 2013, 57:1448-57. |
[37]
|
Slovak R, Ludwig JM, Gettinger SN, et al. Immuno-thermal ablations-boosting the anticancer immune response[J]. J Immunother Cancer, 2017, 5:78. |